UCB

UCB (EBR:UCB) * GSK to acquire from UCB commercial operations and product distribution rights for selected markets in the Far-East, Middle-East, Latin America and Africa

UCB (EBR:UCB) * WILEX to acquire UCB's preclinical oncology portfolio of five programmes * Joint development strategy includes buyback options for UCB * UCB to become a strategic investor in WILEX

UCB (EBR:UCB) Brussels (Belgium), 5 January, 2009 at 6:00 pm CET - Press release - regulated information - UCB announced today that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) relating to the Biologics License Application (BLA) of Cimzia® (certolizumab pegol), the first PEGylated anti-TNF, for the treatment of rheumatoid arthritis (RA).

UCB (EBR:UCB) Brussels (Belgium), December 19, 2008 at 07:00 AM (CET) - press release, regulated information - UCB announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its transdermal patch, Neupro® (rotigotine transdermal system) to treat the signs and symptoms of advanced Parkinson's disease, and as a treatment for the signs and symptoms of moderate to severe primary Restless Legs Syndrome (RLS).

UCB (EBR:UCB) Brussels (Belgium), December 2, 2008 at 07:00 AM (CET) - UCB announced today that its CDP6038 antibody drug candidate targeting IL-6 has achieved a key milestone as the first subjects have been dosed in its Phase 1 'first in human' study.

UCB (EBR:UCB) Preliminary Top Line Results of Phase III Trial Show Significant Decreases in Pain and Fatigue and Improved Daily Function in Fibromyalgia Patients

UCB (EBR:UCB) * FAST 4WARD showed monotherapy Cimzia® 400 mg, dosed every four weeks, provided significant and effective clinical benefits compared to placebo

UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:

UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information:

UCB (EBR:UCB) Brussels, Belgium, October 31, 2008 at 6:00 PM (CET) - press release, regulated information: